Project Grant R03HL174682
Award Date
9/15/24
Completion Date
6/30/26
Dollars Obligated
$123K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...
This $827,753 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop more effective gene-mapping methods for rare polygenic disorders like idiopathic pulmonary fibrosis (IPF). The project has three key objectives: (1) developing a network model-based association test informed by pleiotropy to gene expression traits, (2) creating a rare-variant association test accounting for genetic background using...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $542,402 in funding to support research conducted by the collaborative partnership between Henry Ford Health and Michigan State University Health Sciences. The goal of the project is to identify small molecules that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis (IPF), a devastating lung disease...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,940 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) with a project period from Sep 20, 2024 to Aug 31, 2029. The grant aims to develop a novel mouse model of flow-induced pulmonary hypertension (PH) that better represents the physiological conditions observed in patients with congenital heart disease. Additionally, the project...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
This $342,900 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to define the functional role of lung microfold (M) cells in predisposition to influenza-associated pneumococcal invasion and resulting pneumonia and sepsis. The research aims to identify the intracellular trafficking mechanisms during pneumococcal transcytosis across airway M cells. The work will be conducted at the...
This federal Project Grant award for $595,286.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate a previously unappreciated mechanism of regulating collagen clearance in the lungs. The research seeks to delineate the pathways and upstream/downstream mechanisms governing a cellular homeostatic feedback loop that senses collagen synthesis and regulates its clearance. This work will use mouse...
This federal Project Grant award for $268,500.00, issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development and validation of an AI-based algorithm to quantify pulmonary microvascular injury from single-energy CT scans. The research aims to define a new image-based marker of microvascular alterations in order to investigate the relationship between pulmonary vascular damage and the progression of...
This $5,715,866 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies to substantially reduce the burden of pulmonary fibrosis (PF). The 5-year program will focus on investigating the early, pre-symptomatic progression of familial pulmonary fibrosis (FPF) to identify critical mechanisms driving disease initiation and progression. Key activities include: Analyzing...